Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • JOBS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS SCIENTIFIC ARTICLES

  • Hit-to-lead optimization of a benzene sulfonamide series for potential antileishmanial agents
  • Animal models of Chagas disease and their translational value to drug development
  • Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis

RSS PRESS RELEASES

  • Innovative single-dose oral sleeping sickness treatment to be co-developed by Sanofi and DNDi partnership
  • DNDi short film about new treatment for sleeping sickness awarded Grand Prix at inaugural WHO film festival
  • Up to 45,000 people living with Chagas disease in the US at risk of severe COVID-19 complications

RSS NEWS

  • DNDi Board Member awarded title for his leadership in Malaysian COVID-19 response
  • DNDi in India – Highlights from 2019
  • Five years of the Neglected Tropical Diseases (NTD) Drug Discovery Booster

RSS IN THE MEDIA

  • Weak research funding hampers Africa Covid-19 clinical trials
  • Interview of Dr Bernard Pécoul on sleeping sickness
  • Recibe financiación un proyecto en Granada que busca tratamientos contra enfermedades tropicales

RSS Scientific Articles

  • Hit-to-lead optimization of a benzene sulfonamide series for potential antileishmanial agents
  • Animal models of Chagas disease and their translational value to drug development
  • Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis
  • Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

Subscribe

Sign up for the E-news newsletter! By subscribing, you agree that all info submitted will be processed according to our Privacy Policy. You can unsubscribe any time.

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

DNDi social mission ratio 2019

  • PRIVACY POLICY
  • TERMS OF USE
  • ACCEPTABLE USE POLICY
  • COOKIE POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Read Cookie Policy. Close